Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, ...
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a ...
IDRX-42 continues to demonstrate promising anti-tumor activity with a 29% ORR across all patients (median four prior lines of therapy) and a 53% objective response rate (ORR) in second-line patients ...
Huntsman Cancer Institute at the University of Utah stands at the forefront of innovative cancer research and treatment. Phase 1 clinical trials are key to finding better ways to treat cancer safely ...
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced topline data from the Phase 1 study of CK-4021586 (CK-586). The study met its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results